Dr. Randy Schatzman On Dodging Disruption: The New Fundraising Norm
Source: Cytiva
Dr. Randy Schatzman, CEO at Bolt Biotherapeutics, discusses how his company has adjusted to pandemic-related disruption on the fundraising trail without missing a beat. He walks us through the remote-fundraising strategy that landed Bolt's recent $93.5 million Series C financing round, and how the company is moving towards an IPO in spite of market, civil, and political tumult.
LISTEN TO THE PODCAST!
Log In
Signing up provides unlimited access to:
Free Sign Up
Signing up provides unlimited access to:
- Trend and Leadership Articles
- Case Studies
- Extensive Product Database
- Premium Content
HELLO. PLEASE LOG IN.
X
Not yet a member of Outsourced Pharma? Register today.
ACCOUNT SIGN UP
X
Please fill in your account details
ACCOUNT SIGN UP
This website uses cookies to ensure you get the best experience on our website. Learn more